CSPC's Three Latest Research Findings of Class 1 New Drug Selected for the World Stroke Congress (WSC) (III)

The 14th World Stroke Congress (WSC) was held in Singapore from October 26-29, 2022, by the World Stroke Organization (WSO).

The three latest research findings of CSPC's class I new drug, Butylphthalide (NBP), for treating acute ischemic stroke, were selected for this Congress.

Today, we will present the third finding.

Paper Information

Title: Longitudinal Tracking The Improvement Of White Matter Fiber Tracts In Stroke Patients With Butylphthalide

Abstract ID: 3053

Corresponding author: Zhu Yifei

Organization: The Second Hospital of Hebei Medical University

Background

Existing evidence indicates that changes in white matter fiber tracts after stroke are closely related to neurological deficits. This study used Tract-Based Spatial Statistics (TBSS) based on white matter fiber skeleton to observe the improvement effect of long-term oral administration of NBP on white matter fiber tracts in stroke patients.

Methodology

This study was a randomized, double-blind, placebo-controlled observational study, enrolling a total of 110 stroke patients (56 in the NBP group and 54 in the placebo group). All patients were treated with 2 soft capsules 3 times a day for 24 weeks; DTI images were collected at baseline, 1 month, 3 months, and 6 months after administration, as well as FA values were analyzed.

Findings

Compared with the control group, the FA value of the bilateral corticospinal tract in the test group gradually increased after 6 months of administration (p < 0.05), while the FA value of the control group gradually decreased (p < 0.05). The results showed that the integrity of the white matter fiber tracts in the test group tended to be good, while the integrity of the white matter fiber tracts in the control group was damaged.

Conclusions

Long-term (6 months) oral administration of NBP could sustainably improve the integrity of white matter fiber tracts in stroke patients.